Shanghai Allist Pharmaceuticals Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Shanghai Allist Pharmaceuticals Co., Ltd. carries a market capitalization of 58.76B, placing it among publicly traded companies globally. Its enterprise value stands at 38.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 58.76B |
| Enterprise Value | 38.19B |
Share Statistics
Shanghai Allist Pharmaceuticals Co., Ltd. currently has 450.00M shares outstanding.
| Shares Outstanding | 450.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shanghai Allist Pharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 23.00. The price-to-sales ratio is 9.64, and the price-to-book ratio stands at 16.80.
| PE Ratio | 23.00 |
| PS Ratio | 9.64 |
| PB Ratio | 16.80 |
| P/TBV Ratio | 7.23 |
| P/FCF Ratio | 142.46 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shanghai Allist Pharmaceuticals Co., Ltd. trades at an EV/EBITDA multiple of 18.46 and an EV/FCF ratio of 129.59. The EV/Sales ratio of 8.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.46 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.77 |
| EV / EBITDA | 18.46 |
| EV / EBIT | 18.46 |
| EV / FCF | 129.59 |
Financial Position
Shanghai Allist Pharmaceuticals Co., Ltd. maintains a current ratio of 5.67, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.06, indicating conservative leverage, while an interest coverage ratio of 19,307.28 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.67 |
| Quick Ratio | 4.61 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | 19,307.28 |
Financial Efficiency
Shanghai Allist Pharmaceuticals Co., Ltd. posts a return on equity of 101.50 and a return on invested capital of 32.36.
| Return on Equity (ROE) | 101.50 |
| Return on Assets (ROA) | 30.60 |
| Return on Invested Capital (ROIC) | 32.36 |
| Return on Capital Employed (ROCE) | 101.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.72 |
Taxes
Over the trailing twelve months, Shanghai Allist Pharmaceuticals Co., Ltd. has paid 316.91M in income taxes, reflecting an effective tax rate of 14.80.
| Income Tax | 316.91M |
| Effective Tax Rate | 14.80 |
Stock Price Statistics
Shanghai Allist Pharmaceuticals Co., Ltd.'s stock has gained approximately 41.56548% over the past 52 weeks. The 50-day moving average sits at 92.76, while the 200-day moving average is 98.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | 41.56548% |
| 50-Day Moving Average | 92.76 |
| 200-Day Moving Average | 98.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shanghai Allist Pharmaceuticals Co., Ltd. generated 4.36B in revenue and converted that into 1.82B in net income, yielding earnings per share of 4.05. EBITDA reached 2.07B, while operating income came in at 2.07B.
| Revenue | 4.36B |
| Gross Profit | 4.21B |
| Operating Income | 2.07B |
| Pretax Income | 2.14B |
| Net Income | 1.82B |
| EBITDA | 2.07B |
| EBIT | 2.07B |
| Earnings Per Share (EPS) | 4.05 |
Balance Sheet
Shanghai Allist Pharmaceuticals Co., Ltd. holds 3.78B in cash and equivalents against 3.87M in total debt, resulting in a net debt position of -1.05B. Total book value stands at 2.50B, with working capital of 3.83B providing operational flexibility.
| Cash & Cash Equivalents | 3.78B |
| Total Debt | 3.87M |
| Net Debt | -1.05B |
| Equity (Book Value) | 2.50B |
| Book Value Per Share | 5.54 |
| Working Capital | 3.83B |
Cash Flow
After subtracting -294.62M in capital expenditures, free cash flow totaled -294.62M - equivalent to -0.65 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -294.62M |
| Free Cash Flow | -294.62M |
| FCF Per Share | -0.65 |
Margins
Shanghai Allist Pharmaceuticals Co., Ltd. operates with a gross margin of 96.58, reflecting its pricing power and cost economics. The operating margin of 47.50 and net profit margin of 41.90 provide insight into operational efficiency.
| Gross Margin | 96.58 |
| Operating Margin | 47.50 |
| Pretax Margin | 49.18 |
| Profit Margin | 41.90 |
| EBITDA Margin | 47.50 |
Dividends & Yields
The company's payout ratio of 6.16 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.25 |
| Dividend Yield | N/A |
| Payout Ratio | 6.16 |
| Shareholder Yield | 0.70 |
| FCF Yield | 0.70 |
Scores
Shanghai Allist Pharmaceuticals Co., Ltd. posts an Altman Z-Score of 32.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 32.63 |